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Purpose: To investigate and describe in detail the demographics, functional and anatomic characteristics,
and clinical course of Leber congenital amaurosis (LCA) associated with mutations in the CEP290 gene (LCA-
CEP290) in a large cohort of adults and children.
Design: Retrospective case series.
Participants: Patients with mutations in CEP290 identified at a single UK referral center.
Methods: Review of case notes and results of retinal imaging (color fundus photography, fundus auto-
fluorescence [FAF] imaging, OCT), electrophysiologic assessment, and molecular genetic testing.
Main Outcome Measures: Molecular genetic testing, clinical findings including visual acuity and retinal
imaging, and electrophysiologic assessment.
Results: Forty patients with LCA-CEP290 were identified. The deep intronic mutation c.2991þ1655 A>G
was the most common disease-causing variant (23/40 patients) identified in the compound heterozygous state in
20 patients (50%) and homozygous in 2 patients (5%). Visual acuity (VA) varied from 6/9 to no perception of light,
and only 2 of 12 patients with longitudinal VA data showed deterioration in VA in their better-seeing eye over time.
A normal fundus was found at diagnosis in younger patients (mean age, 1.9 years), with older patients showing
white flecks (mean age, 5.9 years) or pigmentary retinopathy (mean age, 21.7 years). Eleven of 12 patients (92%)
with OCT imaging had preservation of foveal architecture. Ten of 12 patients (83%) with FAF imaging had a
perifoveal hyperautofluorescent ring. Having 2 nonsense CEP290 mutations was associated with worse final VA
and the presence of nonocular features.
Conclusions: Detailed analysis of the clinical phenotype of LCA-CEP290 in a large cohort confirms that there
is a window of opportunity in childhood for therapeutic intervention based on relative structural preservation in the
central cone-rich retina in a significant proportion of patients, with the majority harboring the deep intronic variant
potentially tractable to several planned gene editing approaches. Ophthalmology 2018;125:894-903 ª 2018 by
the American Academy of Ophthalmology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Leber congenital amaurosis (LCA) was first described by
Theodore Leber in 1869 and refers to a heterogeneous group of
retinal disorders with early-onset vision loss, nystagmus, and
an extinguished electroretinogram (ERG).1 Leber later
described a separate group of milder disease phenotypes,
with some preservation of the ERG responses (now referred
to as “early-onset severe retinal dystrophy” [EOSRD] or
“severe early childhood onset retinal dystrophy”).2,3 There is
considerable clinical and genetic overlap between LCA and
EOSRD/severe early childhood onset retinal dystrophy. Leber
congenital amaurosis and EOSRD account for a significant
proportion of blindness in children worldwide,4e6 with an
annual estimated incidence of 1 in 30 000 newborns.7 In the
United Kingdom, 14% of children with newly diagnosed
blindness have LCA/EOSRD.8894 ª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/). Published by Elsevier Inc.Twenty-five causative genes have been identified to date,
accounting for 70% to 80% of all LCA/EOSRD cases.
CEP290 is one of the most common causes, accounting for
15% to 20% of all known cases.9 The intronic variant
c.2991þ1655A>G is the most common pathogenic
mutation, especially in Europe and the United States,7
identified in 77% of all patients in 1 cohort with CEP290-
related disease.10
CEP290 encodes a protein that localizes to the transition
zone of the connecting cilium, including the cilia of pho-
toreceptors11; Leber congenital amaurosis-CEP290 is one of
an increasing number of retinal dystrophies that can be
classified as a ciliopathy.9,12 In addition to isolated LCA/
EOSRD, CEP290 mutations also have been identified in
BardeteBiedl syndrome, SenioreLoken syndrome, Jouberthttps://doi.org/10.1016/j.ophtha.2017.12.013
ISSN 0161-6420/17
Table 1. Molecular Findings in the Study Leber Congenital Amaurosis CEP290 Cohort
Patient
No. GC No. Mutation 1 Effect
Grantham
Scorey Mutation 2 Effect Grantham scorey
1 17585 c.2991þ1655A>G p.(Cys998*) n/a c.2980G>A p.(Glu994Lys) 56 (probably tolerated,
but this missense
mutation results in a
change of charge from
negative to positive
that may render the
CEP290 protein
functionless)
2 18665 c.2991þ1655A>G p.(Cys998*) n/a unknown unknown n/a
3 17243 c.2991þ1655A>G p.(Cys998*) n/a c.1163T>A p.(Leu388*) n/a
4 14293 c.2991þ1655A>G p.(Cys998*) n/a c.2991þ1655A>G p.(Cys998*) n/a
5a 1874 c.4393C>T p.(Arg1465*) n/a c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
5b 1874 c.4393C>T p.(Arg1465*) n/a c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
5c 1874 c.4393C>T p.(Arg1465*) n/a c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
5d 1874 c.4393C>T p.(Arg1465*) n/a c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
5e 1874 c.4393C>T p.(Arg1465*) n/a c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
6 16827 c.2991þ1655A>G p.(Cys998*) n/a c.1984C>T p.(Gln662*) n/a
7 19073 c.4723A>T p.(Lys1575*) n/a c.712G>T p.(Glu238*) n/a
8 19328 c.2991þ1655A>G p.(Cys998*) n/a unknown unknown n/a
9 17668 c.2991þ1655A>G p.(Cys998*) n/a c.6277delG p.(Val2093fs) n/a
10 18259 c.4723A>T p.(Lys1575*) n/a c.4966G>T p.(Glu1656*) n/a
11 18410 c.2991þ1655A>G p.(Cys998*) n/a c.3175dupA p.(Ile1059Asnfs*11) 149z (probably not
tolerated)
12 16596 c.2991þ1655A>G p.(Cys998*) n/a c.2991þ1655A>G p.(Cys998*) n/a
13 17341 c.4723A>T p.(Lys1575*) n/a c.6079delG p.(Glu2027Lysfs*5) 56z (probably tolerated)
14 19709 c.2991þ1655A>G p.(Cys998*) n/a c.1781T>A p.(Leu594*) n/a
15 17947 c.2991þ1655A>G p.(Cys998*) n/a c.384_387delTAGA p.(Asp128Glufs*34) 45z (probably tolerated)
16 19085 c.2991þ1655A>G p.(Cys998*) n/a unknown unknown n/a
17 18805 c.2991þ1655A>G p.(Cys998*) n/a c.1066-1G>A splice n/a
18 19043 c.2991þ1655A>G p.(Cys998*) n/a c.4966G>T p.(Glu1656*) n/a
19 18444 c.2991þ1655A>G p.(Cys998*) n/a c.4723A>T p.(Lys1575*) n/a
20 18269 c.5668G>T p.(Gly1890*) n/a c.5668G>T p.(Gly1890*) n/a
21 23097 c.1681C>T p.(Gln561*) n/a c.7027delG p.(Val2343Phefs*4) 50z (probably tolerated)
22a 15931 c.5777G>C p.(Arg1926Pro) 103 (probably
not tolerated)
c.4966_4967delGA p.(Glu1656Asnfs*3) 42z (probably tolerated)
22b 15931 c.5777G>C p.(Arg1926Pro) 103 (probably
not tolerated)
c.4966_4967delGA p.(Glu1656Asnfs*3) 42z (probably tolerated)
23 17147 c.2991þ1655A>G p.(Cys998*) n/a c.381_382delAGinsT p.(Lys127Asnfs36*) 94z (possibly not
tolerated)
24 16858 c.2991þ1655A>G p.(Cys998*) n/a c.1219_1220delAT p.(Met407Glufs*13) 126z (probably not
tolerated)
25 23818 c.2991þ1655A>G p.(Cys998*) n/a c.7048C>T p.(Gln2350*) n/a
26 18721 c.3175dupA p.(Ile1059Asnfs*11) 149z (probably
not tolerated)
unknown unknown n/a
27 13786 c.2991þ1655A>G p.(Cys998*) n/a c.4966G>T p.(Glu1656*) n/a
28 18481 c.2991þ1655 A>G p.(Cys998*) n/a c.5941G>T p.(Glu1981*) n/a
29 19641 c.2991þ1655A>G p.(Cys998*) n/a c.4801C>T p.(Gln1601*) n/a
30 16829 c.148C>T p.His50Tyr 83 (possibly
not tolerated)
c.148C>T p.(His50Tyr) 83 (possibly not tolerated)
31a 24072 c.4661_4663delAAG p.(1554delGlu) n/a c.4661_4663delAAG p.(1554delGlu) n/a
31b 24072 c.4661_4663delAAG p.(1554delGlu) n/a c.4661_4663delAAG p.(1554delGlu) n/a
31c 24072 c.4661_4663delAAG p.(1554delGlu) n/a c.4661_4663delAAG p.(1554delGlu) n/a
32 24225 c.2991þ1655A>G p.(Cys998*) n/a c.270_274delAGTAA p.(Lys90Asnfs*6) 94z (possibly not
tolerated)
33 25255 c.2991þ1655A>G p.(Cys998*) n/a c.3175dupA p.(Ile1059Asnfs*11) 149z (probably not
tolerated)
c. ¼ coding region; del ¼ deletion; dup ¼ duplication; fs ¼ frameshift; fs*digit ¼ frameshift that results in a translation termination codon occurring
downstream at the designated number of amino acids; n/a ¼ not applicable; p. ¼ protein.
*Translation termination codon.
yGrantham scoring, where <60 ¼ probably tolerated; 61e99 ¼ possibly not tolerated; >100 ¼ probably not tolerated.
zDespite the fact that a missense mutation may be assigned a Grantham score, these mutations result in frameshifts that truncated the CEP290 protein, thus
rendering the gene product functionless.
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Figure 1. Schematic diagram showing the CEP290 gene and the location of the mutations identified in our cohort. LCA ¼ Leber congenital amaurosis.
Ophthalmology Volume 125, Number 6, June 2018syndrome, and MeckeleGruber syndrome.7 No definitive
genotype-phenotype correlation has been established for
isolated ocular versus syndromic CEP290-associated
disease.3,13
Since the development of gene-based therapy for RPE65-
associated LCA/EOSRD, there has been considerable in-
terest in novel treatments for other molecular forms of LCA/
EOSRD.3,14 Lentiviral vector gene replacement, antisense
oligonucleotide, and CRISPR/Cas9-based techniques are all
under active investigation as viable interventions in CEP290
LCA/EOSRD.15e19
The current study provides a detailed characterization of
the clinical phenotype and natural history in a large number
of patients with CEP290 LCA/EOSRD seen at a single
institution, which will help to provide improved genetic
counseling and advice on prognosis, and to assist in the
preparation and design of anticipated clinical trials of novel
therapies.Methods
Patient Identification and Assessment
Patients harboring likely disease-causing variants in CEP290 were
identified from the Moorfields Eye Hospital Inherited Eye Disease
database. Patients were included in this database after obtaining
informed consent. This retrospective study adhered to the tenets of896the Declaration of Helsinki and was approved by the Moorfields
Eye Hospital ethics committee.
Clinical notes, imaging, and electrophysiologic testing were
reviewed. Clinical data extracted included visual acuity (VA),
subjective and objective refraction, slit-lamp biomicroscopy, and
fundoscopy findings. OCT, fundus autofluorescence (FAF) imag-
ing, and color fundus photography were reviewed when available.
Fundus photographs were obtained with a TRC-50LA Retinal
fundus camera (Topcon, Tokyo, Japan) or Optos wide-field camera
(Optos Panoramic 200; Optos PLC., Scotland, UK). Fundus
autofluorescence images were obtained with Spectralis HRA OCT
(Heidelberg Engineering, Heidelberg, Germany) or Optos wide-
field camera. Retinal lamination and central retinal thickness
were evaluated using the Spectralis HRA OCT (Heidelberg Engi-
neering). Full-field and pattern electroretinogram (PERG) incor-
porated the International Society for Clinical Electrophysiology of
Vision standards,20,21 except in young patients who underwent
ERG testing with skin electrodes without mydriasis, using a pre-
viously reported protocol.22Molecular Diagnosis
The majority of patients were screened using a diagnostic targeted
next-generation sequencing panel for retinal dystrophy. Others
were ascertained via research-based whole exome sequencing or
the Asper microarray chip (Asper, Tartu, Estonia), or in targeted
Sanger sequencing of CEP290. All patients with 1 allele identified
from the Asper chip were subjected to Sanger sequencing to
identify the second allele.
Table 2. Predicted Effect of CEP290 Mutations
Predicted Effect
No. (Total [ 80, 2
Alleles per Patient) Frequency
Termination 60 75%
Substitution (missense) 10 12.5%
In-frame amino acid deletion 6 7.5%
Second mutation unknown 4 5%
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Molecular Genetics
Table 1 and Figure 1 detail the molecular findings in our cohort of
40 LCA-CEP290 patients, including 3 families with multiple
affected members (patients 5a to 5e, 22a and 22b, and 31a to
31c), with the remaining patients being simplex cases. Grantham
score is provided when appropriate.23 The majority of patients
had 2 CEP290 variants identified (n ¼ 36, 90%), with the rest
having 1 mutation identified to date (n ¼ 4, 10%). The deep
intronic mutation c.2991þ1655A>G was the most common
mutation (23/40 patients; 57.5%), identified in the compound
heterozygous state in 20 patients (50%) and homozygous in 2
patients (5%). The effects of the CEP290 mutations identified in
our cohort are summarized in Table 2. The majority (75%) of
variants encoded for premature stop codons, which would lead to
protein truncation and dysfunction due to the loss of criticalTable 3. Clinical Findings in the CEP290 Cohort
Patient (n) 40
Age at presentation (median, range) 0 0e4
Female (n, percentage) 15 38%
Refraction (n, percentage)
Hyperopia 19 48%
Myopia 1 3%
Plano 5 13%
Not available 15 38%
VA in best-seeing eye (n, percentage)
No perception of light 7 18%
Perception of light 11 28%
Does not fix and follow 3 8%
Hand movements 1 3%
Fixate on large objects 2 5%
6/60e1/60 8 20%
6/48 1 3%
6/36 4 10%
6/15 1 3%
6/12 1 3%
6/9 1 3%
ERG (n, percentage)
Extinguished 22 55%
Residual 30 Hz flicker 1 2.5%
Not available 17 42.5%
Systemic involvement (n, percentage)
Joubert syndrome 1 3%
Renal failure 1 3%
Developmental delay/autism 6 15%
Other neurologic disorders 2 5%
Total 10 25%
ERG ¼ electroretinogram; VA ¼ visual acuity.CEP290 functional domains.11 More important, premature stop
codons result in nonsense-mediated decay, which would remove
these aberrant transcripts, thus significantly decreasing the steady-
state of CEP290 mRNA levels.24 Conversely, only 12.5% of
variants result in missense amino acid substitutions, namely,
p.(His50Tyr) (a positive to a neutral charge), p.(Glu994Lys) (a
negative to a positive charge), and p.(Arg1926Pro) (a positive to
a neutral charge). Given that all 3 substitutions constitute
changes in the net charge of the amino acid side changes, they
are likely to induce significant effects on CEP290 function.
Clinical Findings
Findings are summarized in Tables 3e6 and Figures 2e7. All
patients had reduced vision or nystagmus noted within the first 4
years of life. Visual acuity loss was marked and of early onset,
with 18% (n ¼ 7) of patients having no perception of light in both
eyes at presentation. Forty percent (n ¼ 16) of all patients were
able to record a VA on a Snellen chart, with 7.5% (n ¼ 3) having
a VA of better or equal to 6/15 in their better seeing eye and 80%
(n ¼ 32) having a VA of worse or equal to 6/60. In the 12 patients
with serial VA measurement (Table 5), 4 (33%) had worsening of
their VA over time. Two patients (17%) had visual deterioration
in both eyes, 1 deteriorated from 6/18 right and 6/12 left to 6/36
in both eyes between 35 and 50 years of age, and 1 deteriorated
from 6/30 to 2/60 in both eyes between 3 and 7 years of age. Two
patients had deterioration in vision in the worst seeing eye only,
1 from 6/36 to 6/150 between 25 and 42 years of age, whereas the
best-seeing eye was maintained at 6/30, and the other went from
perception of light in both eyes to no perception of light in 1 eye.
There were no patients with light perception or better VA at
presentation, who subsequently progressed to no light perception
in both eyes during follow-up assessment. Patients harboring 1 or
more missense mutations or in-frame deletions had a final VA of
1/60 or better compared with those with 2 nonsense mutations
who had a worse VA (75% vs. 26%) (Table 6).
Of the 25 patients in whom refraction data were available, 19
(76%) were hyperopic, and only 1 (4%) was myopic. The
remaining 5 patients did not have a significant refractive error.
Typical fundus images are shown in Figures 2 and 3. A normal
fundus examination was observed in 43% (n ¼ 17) of patients,
17% (n ¼ 7) had white flecks in the periphery, and peripheral
pigmentary changes were seen in 40% (n ¼ 16) (Table 4). On
the basis of the last recorded fundus examination findings, those
with normal fundi (mean, 1.9 years; range, 0e21 years; standard
deviation [SD], 5 years) tended to be the youngest, followed by
those with white flecks (mean, 5.9 years; range, 2e13 years; SD,
4.3 years) and those with pigmentary retinopathy (mean, 19.7
years; range, 1e54 years; SD, 14.6 years), suggesting the
evolution of the retinal phenotype from normal or fleck
retinopathy to pigmentary retinopathy over time. However,
longitudinal data were not available to show the sequential
changes in retinal phenotype over time in the same patient.Table 4. Retinal Findings and Association with Age of
Examination
Retinal Findings n Percentage Mean Age, yrs SD
Pigmentary retinopathy 16 40% 19.7 14.6
White flecks only 7 18% 5.9 4.3
Normal 17 43% 1.9 4.8
SD ¼ standard deviation.
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Table 5. Serial Measurement of Visual Acuity in Those with Longitudinal Records
Patient No.
Initial VA Age at Initial
Examination
Final VA Age at Final
Examination
Length of
Follow-up (yrs)Right Eye Left Eye Right Eye Left Eye
3 PL PL 29 NPL PL 33 4
4 6/36 6/36 7 6/150 6/30 42 35
5a 6/60 6/60 12 6/48 6/60 33 21
5c 6/60 6/60 10 6/60 6/60 34 24
5d 6/60 6/60 19 6/60 6/60 29 10
6 NPL NPL 5 NPL NPL 11 6
10 6/30 6/30 3 2/60 2/60 7 4
12 PL PL 0 PL PL 15 15
17 NPL NPL 2 NPL NPL 5 3
22a 6/18 6/12 35 6/36 6/36 50 15
29 PL PL 0 PL PL 4 4
30 6/30 6/30 4 6/12 6/12 15 11
NPL ¼ no light perception; PL ¼ light perception; VA ¼ visual acuity.
Ophthalmology Volume 125, Number 6, June 2018Figure 3 shows the progressive increase in pigment in the
peripheral retina over 4 years in an 18-year-old patient.
A nonocular condition was present in 25% of patients. The
most common association was a delay in development or autism
(15%). Joubert syndrome and renal disease were uncommon, with
only 1 patient (3%) with each condition in our cohort. This may
represent an ascertainment bias because patients were recruited
from a stand-alone eye hospital. All patients with nonocular con-
dition have 2 nonsense CEP290 mutations.Retinal Imaging
Thirteen patients (31%) had OCT and FAF imaging with the
Spectralis imaging system. On FAF imaging, 10 of 12 patients
(83%) had a perifoveal hyperautofluorescent ring, with peripheral
loss of FAF (Fig 4). The remaining 2 patients (17%) had parafoveal
and peripheral loss of FAF, with preservation of FAF at the fovea
(Fig 5).
Eleven of 12 patients (92%) had relative preservation of foveal
architecture, with a loss of peripheral macular outer retinal struc-
ture on OCT imaging (Figs 5 and 6). The remaining subject had
total loss of the outer retina. Eight patients had serial OCT
imaging, with 2 patients showing evidence of progressive loss of
the inner segment ellipsoid line over time (Figs 5 and 6). The
youngest patient in the series, patient 33 (22 months old) had
handheld Bioptigen (Morrisville, NC) OCT imaging that revealed
relatively intact outer retinal structure (Fig 7).Table 6. Association between Predicted Amino Acid Effect and
Final Visual Acuity, Excluding Those with Unknown Second
Mutation
Mutations
Final VA
1/60 <1/60
1 missense mutations or an in-frame deletion 9 3
Both nonsense mutations 6 17
VA ¼ visual acuity.
898Electrophysiologic Assessment
All young patients tested with skin electrodes and 2 adult patients
(27 and 30 years of age) tested with corneal electrodes had unde-
tectable photopic and scotopic ERGs in keeping with a severe
photoreceptor dystrophy. One other adult patient had undetectable
photopic (light adaptation 3.0 and 30 Hz) ERGs and grossly
abnormal scotopic (dark adaptation 0.01 and 10.0) ERGs at the age
of 34 years that worsened over the following 11 years, consistent
with a progressive cone-rod dystrophy. In 1 adult, the PERG was
technically poor because of nystagmus, but in 2 others who un-
derwent testing (1 adult and 1 child aged 20 months), the PERG
was undetectable in keeping with severe macular involvement.Discussion
Mutations in CEP290 account for 15% to 20% of all cases
of LCA/EOSRD.9 In this study, we describe a large group of
patients who have undergone detailed clinical phenotyping
at a single institution. The majority of patients in this
cohort had severe visual loss at baseline, and in those with
longitudinal data, many did not show deterioration in their
VA. Hyperopia was the most common refractive error,
and this is consistent with other forms of LCA.25 The
retinal appearance was variable, with younger subjects
being more likely to have a normal fundus appearance or
peripheral white flecks without pigmentation. Older
patients commonly showed evidence of peripheral retinal
pigment migration. This variation with age has been
reported in other studies7,9,10,26 and suggests that, in
contrast to the relatively stable central retinal function, there
may be progressive peripheral photoreceptor cell death.
Despite a profoundly abnormal or extinguished ERG
indicating severe global impairment of outer retinal func-
tion, we found that the outer retinal structure (inner segment
ellipsoid and outer nuclear layers) at the fovea on OCT
appeared to be relatively well preserved. This is consistent
with findings in other studies.7,27,28 In particular, a recent
study reported the presence of central photoreceptors in a
cohort of patients with CEP290 LCA, similar to our
Figure 2. Optos (Optos Panoramic 200; Optos PLC., Scotland, UK) color fundal image of the right eye of patient 31a (A) showing the typical white flecks
found in CEP290 Leber congenital amaurosis (LCA). Very mild pigmentary changes were also observed. This is compared with the Optos color fundal image
of the right eye of patient 5e (B) showing severe peripheral retinal atrophy and pigment formation.
Sheck et al  LCA Associated with CEP290 Mutationsfindings.28 The same study also showed a loss of rod
function in these patients, which agrees with our ERG
findings.28 This leads to optimism that restoration of coneFigure 3. Color fundus photograph showing mild pigmentary changes in
the right retina in patient 5c at 23 years of age (A) and increased
pigmentary change 4 years later (B).function may be possible using gene therapy-based ap-
proaches.29 Such potential therapeutic approaches have been
explored in vitro with a lentiviral vector containing human
CEP290 and has been shown to effectively transduce
patient-specific induced pluripotent stem cell-derived
photoreceptor precursor cells and rescue the cellular
phenotype.17 Other studies have focused on the common
deep intronic CEP290 mutation, which creates a viable
cryptic splice donor site that leads to the insertion of an
additional exon that includes a sequence that encodes for
a premature stop codon. These approaches have included
the use of antisense oligonucleotide-mediated exon skip-
ping to abrogate the disease-causing variant or correction of
the splice defect using CRISPR/Cas9-mediated gene edit-
ing.15,18,19 Both of these novel approaches show great
promise and human clinical trials are anticipated in the near
future.
There are several potential challenges in the design of
therapeutic trials for CEP290 LCA, including eligibility
criteria and outcome measures. Visual acuity will likely be
insensitive partly because of the often poor VA at baseline.
An improvement in ocular motor control and in the ability to
navigate a standardized and validated mobility course may
be useful functional measures. A global measure of light
sensitivity, such as the full-field light sensitivity threshold
test, which has been developed for patients with very poor
vision, also may be valuable. Pupillometry may be infor-
mative, whereas electrophysiologic assessment is unlikely to
be adequately sensitive, with additional reliability/feasibility
challenges due to nystagmus. Spectral domain OCT will be
valuable in determining any changes in foveal structure,
although image acquisition may be challenging given poor
fixation/nystagmus.
In patients with the milder form of LCA/EOSRD, caused
by mutations in RPE65, gene therapy results in an
improvement in visual function, potentially to a greater899
Figure 4. Optos fundus autofluorescence (FAF) of the left eye of patient 25 (A) showing central hyperautofluorescent ring with peripheral loss of auto-
fluorescence compared with Optos FAF of patient 22a (B) showing loss of autofluorescence in the far periphery and in the paramacula region.
Ophthalmology Volume 125, Number 6, June 2018extent in younger patients.30 However, LCA-CEP290 is
associated with far more profound visual impairment at an
earlier age (from birth/early infancy) compared with
RPE65 deficiency; therefore, visual cortical plasticity may
be a more significant limitation to treatment response.
Novel therapies may need to be given in infancy in most
subjects to achieve the best visual outcome.
The majority of patients in our cohort had ocular
involvement only. Joubert syndrome was diagnosed in 1
patient, and 1 patient had renal failure. Neurologic disorders
(seizures and microcephaly), developmental delay, and
autism were the most common nonocular features found inFigure 5. The OCT images of patient 22a showing preservation of left foveal o
(B). Triangles denote termination of inner/outer segment line.
900this cohort. The fact that the subjects were recruited from an
eye hospital, and visual loss was the predominant early
symptom, may have led to some ascertainment basis.
The deep intronic mutation, c.2991þ1655A>G, was the
most common variant in our cohort, with 55% of patients
harboring it in the heterozygous or homozygous state, which
is consistent with previous reports.7 Of note, missense
variants were rare. A review of all CEP290 mutations
reported as “pathogenic” or “likely pathogenic” on the
ClinVar database showed that only 2 of 89 such mutations
were missense mutations.31 There were no missense
variants in another large cohort.7 This suggests thatuter retinal architecture at 36 years of age (A) and progression over 6 years
Figure 6. The OCT images of the right eye of patient 25 at 14 (A) and 18 years of age (B) showing progressive loss of the inner segment/outer segment line
(triangle).
Sheck et al  LCA Associated with CEP290 Mutationsmissense variants are well tolerated and do not sufficiently
abrogate CEP290 protein structure or function, or that the
reported missense variants in LCA-CEP290 may
functionally act like null alleles. A study on the effect of
CEP290 in vitro showed that full-length CEP290 protein
exhibited attenuated activity when compared with truncation
mutants lacking the N or C terminus, suggesting the N and
C terminus of the CEP290 protein have a regulatory effect to
explain the pathogenic effect of nonsense mutations.32
Consistent with this, in our study, patients with 2Figure 7. Handheld Bioptigen (Morrisville, NC) OCT imaging of the left
eye of patient 33 (22 months old) that revealed relatively intact outer
retinal structure.nonsense CEP290 mutations had a worse final VA.
Furthermore, all patients with systemic features had 2
nonsense CEP290 mutations in our cohort.
Early molecular diagnosis of CEP290-related retinal dys-
trophy is critically important, because this allows the provi-
sion of better informed advice on prognosis and will prompt
further investigation to rule out associated systemic disease.
Furthermore, novel therapies for LCA-CEP290 are under
development and clinical trials are anticipated in the near
future. Our study provides key information about the clinical
phenotype and natural history of LCA-CEP290, which will
help inform patient selection and study design for such trials.
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michaelides@moorfields.nhs.uk.Pictures & PerspectivesPseudohemangioma in Nonarteritic Anterior Ischemic
Optic Neuropathy
A 55-year-old man with a history of systemic hypertension
awoke with painless onset of a “grey smudge” in the infer-
onasal visual field in the right eye 7 weeks prior. On
presentation, visual acuities were 20/15 in both eyes (OU)
without dyschromatopsia. A relative afferent pupillary defect
was noted on the right. Automated perimetry showed a nasal
hemifield deficit in the right eye (Fig 1A; inset). Funduscopy
revealed inferior focal optic disc edema with hemorrhage
(Fig 1A). Fluorescein angiography (20 sec) showed focally
dilated peripapillary capillaries inferotemporally (Fig 1B).
Pseudohemangiomas are vascular anomalies of the optic disc
arising after an ischemic event. (Magnified version of Fig 1A-B
is available online at www.aaojournal.org).
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